895 results on '"Nashan, B"'
Search Results
152. 59 Dual targeting of mTOR and HSP90 for therapy of pancreato-biliary carcinomas
153. 556 Therapeutic siRNA delivery against PKN3 improves the antineoplastic efficacy of gemcitabine in an orthotopic pancreatic cancer model
154. LIVING KIDNEY DONORSʼ QUALITY OF LIFE IN THE FIRST POSTOPERATIVE YEAR: A PROSPECTIVE LONGITUDINAL STUDY WITH AN APPROPRIATE REFERENCE GROUP
155. MAINTENANCE IMMUNOSUPPRESSION WITH CNI AND EVEROLIMUS AFTER ABO INCOMPATIBLE LIVING RELATED KIDNEY TRANSPLANTATION.
156. THE EFFECT OF TASOCITINIB (CP-690,550) ON THE INCIDENCE OF ACUTE REJECTION AND RENAL FUNCTION IN DE NOVO KIDNEY TRANSPLANT PATIENTS: 6-MONTH INTERIM ANALYSIS OF A PHASE 2B STUDY
157. OUTCOME FOLLOWING PEDIATRIC LIVER TRANSPLANTATION DEPENDING ON DONOR AGE - ESPECIALLY VERY YOUNG DONORS
158. LONG-TERM RESULTS OF COMBINED LIVER AND KIDNEY TRANSPLANTATION (LKTX) IN CHILDREN WITH AUTOSOMAL RECESSIVE INHERITED POLYCYSTIC KIDNEY DISEASE (ARPKD)
159. ANTIVIRAL TREATMENT OF HCV RECURRENCE AFTER LIVER TRANSPLANTATION: IMPACT ON COSTS AND QUALITY OF LIFE.
160. OUTCOME OF LIVER RETRANSPLANTATION IN CHILDREN - IMPACT OF EARLY AND LATE RETRANSPLANTATION
161. ARE LIVER TRANSPLANTED CHILDREN MORE IMPULSIVE? ATTENTION AND EXECUTIVE FUNCTIONING AFTER PEDIATRIC LIVER TRANSPLANTATION
162. SURGICAL ASPECTS OF COMBINED LIVER AND KIDNEY TRANSPLANTATION IN CHILDREN
163. ABSOLUTE AND RELATIVE NFAT REGULATED GENE EXPRESSION UNDER CYCLOSPORINE A TREATMENT
164. URINARY ETHYL GLUCURONIDE TESTING FOR DETECTION OF ALCOHOL CONSUMPTION IS SUPERIOR TO COMMON ALCOHOL MARKERS IN LIVER TRANSPLANT CANDIDATES AND RECIPIENTS
165. LIVER TRANSPLANTATION WITH DONOR AGED 70 OR ABOVE: IS IT JUSTIFIED?
166. Localization of apoptosis proteins and lymphocyte subsets in chronic rejection of human liver allograft
167. Photodynamische Therapie der extrahepatischen Gallenwege mit Temoporfin: Sicherheit und Überleben
168. Die Lebertransplantation im Kindesalter
169. 142: The Role of Alloantibody in the Development of Cardiac Allograft Vasculopathy
170. GENOTYPE AND EARLY VIRAL RESPONSE BUT NOT RIBAVIRIN DRUG LEVEL MONITORING ARE PREDICTIVE FACTORS FOR RESPONSE TO TREATMENT OF HCV REINFECTION AFTER LIVER TRANSPLANT
171. POSTOPERATIVE CARE AFTER PEDIATRIC COMBINED HEPATORENAL TRANSPLANTATION (CHRTX)
172. Aktuelle Therapie der primären sklerosierenden Cholangitis*
173. Aktuelle Diagnostik der primären sklerosierenden Cholangitis*
174. Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis
175. The Type of Arterial Anastomosis Influences Hepatic Hemodynamics and Overall Survival in Liver Graft Recipients
176. Conversion From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Stable Maintenance Renal Transplant Patients: Pooled Results From Three International, Multicenter Studies
177. Skin tumors in organ-transplant recipients
178. Coagulation disorder during liver transplantation
179. Reduction of acute allograft rejection by daclizumab
180. Conversion to Enteric-Coated Mycophenolate Sodium From Various Doses of Mycophenolate Mofetil: Results of a Prospective International Multicenter Trial in Maintenance Renal Transplant Patients Receiving Cyclosporine
181. MDR1 C3435T Polymorphisms Correlate With Cyclosporine Levels in De Novo Renal Recipients
182. PUK8 2-HOUR POST DOSE (C2) MONITORING VERSUS TROUGH (C0) MONITORING OF NEORAL: AN ECONOMIC EVALUATION
183. Wie und durch welche Faktoren verändern sich die hämodynamischen Parameter und die Organgrößen bei lebertransplantierten Patienten?
184. LONG TERM ANALYSIS OF RENAL GRAFT RECIPIENTS PARTICIPATING IN THE PHASE III MMF AND TACROLIMUS TRIALS
185. SIROLIMUS TREATMENT PATTERNS AND FIRST YEAR OUTCOMES IN RENAL TRANSPLANT RECIPIENTS UNDER CONDITIONS OF NORMAL PRACTICE: THE RAPAMUNE® OUTCOMES ASSESSMENT REGISTRY (ROAR™)
186. THE USE OF DACLIZUMAB AND MYCOPHENOLATE MOFETIL IN COMBINATION WITH CORTICOSTEROIDS AND CYCLOSPORINE (LOW DOSE VERSUS LOW DOSE FOLLOWED BY WITHDRAWAL) TO OPTIMIZE RENAL FUNCTION IN RECIPIENTS OF RENAL ALLOGRAFTS
187. CO-STIMULATION BLOCKADE WITH LEA29Y IN A CALCINEURIN INHIBITOR FREE MAINTENANCE REGIMEN IN RENAL TRANSPLANT: 6-MONTH EFFICACY AND SAFETY
188. CONVERSION TO ENTERIC-COATED MYCOPHENOLATE SODIUM FROM MMF IN MAINTENANCE RENAL TRANSPLANT PATIENTS: 3 MONTHS INTERIM ANALYSIS
189. POLYMORPHISMS OF MDR1 AND CYCLOSPORINE ABSORPTION IN DE NOVO RENAL TRANSPLANT PATIENTS
190. IMPROVEMENT OF CHRONIC ALLOGRAFT NEPHROPATHY IN A NUDE RAT MODEL WITH THERAPEUTIC TREATMENT WITH EVEROLIMUS
191. LIVING DONOR NEPHRECTOMY: CLASSICAL FLANK INCISION VS. ANTERIOR VERTICAL MINI-INCISION.
192. REDUCTION OF ACUTE REJECTION AFTER LIVER TRANSPLANTATION BY A NOVEL CICLOSPORINE-BASED PROTOCOL
193. CHRONIC ALLOGRAFT NEPHROPATHY IN A RAT MODEL WITH COMPLETE MHC MISMATCH: EFFECTS OF THERAPEUTIC TREATMENT WITH FTY 720
194. Severe Exacerbation of Chronic Hepatitis B after Emergence of Lamivudine Resistance in a Cirrhotic Patient: Immediate Switch to Adefovir Dipivoxil Appears to be Indicated
195. Hörprobleme bei Patienten nach Lebertransplantation– Eine neue Nebenwirkung unter Immunsuppression?
196. 12 Active immunization after liver transplantation for HBV related liver disease: Failure to induce HBV-specific humoral and cellular immune responses
197. Lebendnierenspende
198. HBSAG level at time of olt determines hepatitis B immunoglobulin dose required for elimination of HBSAG after olt in patients with HBV cirrhosis
199. SUCCESSFUL OUTCOME OF ACUTE GRAFT-VERSUS-HOST DISEASE IN A LIVER ALLOGRAFT RECIPIENT BY WITHDRAWAL OF IMMUNOSUPPRESSION
200. Stellenwert der Lebertransplantation beim hepatozellulären Karzinom
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.